Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 1211 • 2015 ACR/ARHP Annual Meeting
Shift of Rheumatoid Arthritis Onset Toward Old Age in Japan Based on a Nationwide Cohort Database
Eri Kimura¹, Tetsuji Sawada², Koichiro Tahara¹, Haeru Hayashi¹, Mayu Tago¹, Hiroaki Mori¹, Toshihiro Matsui³, Jinju Nishino⁴ and Shigeto Tohma⁵, ¹Rheumatology, Tokyo Medical University, Tokyo, Japan, ²Rheumatology, Tokyo Medical University, Shinjuku Tokyo, Japan, ³Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Sagamihara, Kanagawa, Japan, ⁴Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, ⁵Department of Rheumatology, National Hospital Organization Sagamihara Hospital, Kanagawa, Japan
Background/Purpose: Previous studies from Western countries have demonstrated that the incidence of rheumatoid arthritis (RA) increases with age and the age of RA onset was…
Abstract Number: 1657 • 2015 ACR/ARHP Annual Meeting
Evaluation of Bone and Joint Proteins for Prognostic Association with Radiographic Progression and Disease Activity in Methotrexate Inadequate Responder Rheumatoid Arthritis Patients in a Sarilumab Phase 3 Study
Anita Boyapati¹, Jérôme Msihid², Jennifer D Hamilton¹, Cem Gabay³, Neil Graham¹ and Stefano Fiore⁴, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi R&D, France, Chilly-Mazarin, NJ, France, ³Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁴Sanofi, Bridgewater, NJ
Background/Purpose: In patients with early RA, autoantibodies, elevated MMP-3, and acute phase proteins are prognostic biomarkers of joint damage and disease activity. However, the ability…
Abstract Number: 2746 • 2015 ACR/ARHP Annual Meeting
Comparison Study of Tests Available to Monitor Tocilizumab Therapy in Rheumatic Patients
Sergio Martín^1,2, Ainhoa Ruiz del Agua², Nerea Torres², Dora Pascual-Salcedo³, Chamaida Plasencia⁴, Teresa Jurado⁵, Alejandro Balsa⁶, Begoña Ruiz-Argüello², Antonio Martínez², Rosaura Navarro⁷ and Daniel Nagore², ¹Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU (Convocatoria ZabaldUZ, UPV/EHU; Departamento de Educación, Universidades e Investigación del Gobierno Vasco, Ref. IT687-13), Leioa, Spain, ²R&D, Progenika-Grifols, Derio, Spain, ³Immunology Unit, La Paz University Hospital-Immunology, Madrid, Spain, ⁴Rheumatology Unit, La Paz University Hospital-Rheumatology, Madrid, Spain, ⁵Immunology, La Paz University Hospital-Idipaz, Madrid, Spain, ⁶Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁷Department of Physiology, Medicine and Dentistry School, University of the Basque Country UPV/EHU, Leioa, Spain
Background/Purpose: The options for treatment of rheumatic diseases is constantly growing. Tocilizumab (TCZ) is an anti-interleukin 6 receptor monoclonal antibody indicated for the treatment of severe…
Abstract Number: 153 • 2015 ACR/ARHP Annual Meeting
Utility of Ultrasound Synovitis Assessment As a Predictor of Flares in Clinically Inactive Joints
Tomas Cazenave¹, Christian A. Waimann², Natalia Zamora¹, Gustavo Citera¹ and Marcos G. Rosemffet¹, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Hospital Dr. Hector Cura, Olavarria, Argentina
Background/Purpose: Several ultrasound (US) studies have shown a high frequency of inflammation in clinically inactive joints of rheumatoid arthritis (RA)patients. There is controversy in the…
Abstract Number: 1219 • 2015 ACR/ARHP Annual Meeting
Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Poland: First Nationwide Study
Bogdan Batko¹, Marcin Stajszczyk², Jerzy Swierkot³, Filip Raciborski⁴ and Piotr Wiland³, ¹Rheumatology, J. Dietl Specialist Hospital, Krakow, Poland, ²Department of Reumatology and Autoimmune Diseases, Silesian Rheumatology Center, Ustron, Poland, ³Department of Rheumatology and Internal Medicine, Wroclaw Medical University, Wroclaw, Poland, ⁴Department of Epidemiology and Health Promotion, Institute of Rheumatology, Warsaw, Poland
Background/Purpose: The prevalence of rheumatoid arthritis (RA) in Europe varies from a geographical standpoint. Knowledge of the occurrence of RA is valuable for policy makers…
Abstract Number: 1672 • 2015 ACR/ARHP Annual Meeting
One-Year Safety of Sirukumab Monotherapy: Results from a Randomized, Double-Blind, Parallel-Group, Multicenter Study in Japanese Subjects with Moderate to Severe Rheumatoid Arthritis
Tsutomu Takeuchi¹, Hisashi Yamanaka², Masayoshi Harigai³, Ryo Tamamura⁴, Yuchi Kato⁴, Yoshifumi Ukyo⁴, Toshikazu Nakano⁴, Takayuki Ota⁴, Benjamin Hsu⁵ and Yoshiya Tanaka⁶, ¹Keio University School of Medicine, Tokyo, Japan, ²Dept. of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ³Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Janssen Pharmaceutical K.K., Tokyo, Japan, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶The First Dept. of Internal Medicine, University of Occupational & Environmental Health, Kitakyusyu, Japan
Background/Purpose: Interleukin-6 (IL-6) is a pleiotropic cytokine known for its proinflammatory functions. In rheumatoid arthritis (RA), increased concentrations of IL-6 may stimulate leukocyte recruitment to…
Abstract Number: 2760 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Sarilumab Plus MTX in Subgroups of Patients with Rheumatoid Arthritis in a Phase 3 Study
Arthur Kavanaugh¹, Alan J. Kivitz², P Miranda³, Stefano Fiore⁴, Jonathan Fay⁵, Chunpeng Fan⁶, Janet van Adelsberg⁷ and T. W. J. Huizinga⁸, ¹University of California San Diego, La Jolla, CA, ²Altoona Center for Clinical Research, Duncansville, PA, ³Centro De Estudios Reumatológicos, Santiago, Chile, ⁴Sanofi, Bridgewater, NJ, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Biostatistics, Sanofi, Bridgewater, NJ, ⁷Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁸Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The investigational drug sarilumab is a human mAb directed against the IL-6 receptor.1 The phase 3 part of MOBILITY (NCT01061736) examined sarilumab + MTX…
Abstract Number: 162 • 2015 ACR/ARHP Annual Meeting
Ultrasonography Versus Clinical Examination in Early DMARD-Naïve Rheumatoid Arthritis – a Comparative Study of Synovitis on the Individual Joint Level
Lena B. Nordberg¹, Elisabeth Lie¹, Siri Lillegraven¹, Anna-Birgitte Aga¹, Inge C Olsen², Hilde Berner Hammer³, Till Uhlig⁴, Désirée van der Heijde⁵, Tore K. Kvien¹, Espen A. Haavardsholm¹ and the ARCTIC Study Group, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Dept. of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Ultrasonography (US) is increasingly accepted as an important tool in diagnosis and management of rheumatoid arthritis (RA). However, it is not well known to…
Abstract Number: 1222 • 2015 ACR/ARHP Annual Meeting
The Risk of Tuberculosis (TB) in Rheumatoid Arthritis Patients Treated with TNF Inhibitors and the Safety of Resuming Biologic Dmards for Patients Who Developed TB after Anti-TNF Treatment
Soo-Kyung Cho¹, Dam Kim¹, Hye-Jin Jeong², Il Woong Sohn², Soyoung Won³, Minkyung Han³, Jiyoung Lee³, Eun Jin Jang⁴, Sang-Cheol Bae¹ and Yoon-Kyoung Sung¹, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ²Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ³Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, ⁴Information Statistics, Andong National University, Andong-si, South Korea
Background/Purpose: The association between TNF inhibitor (TNFI) treatment and the development of tuberculosis (TB) has been confirmed through several observational studies. Current guidelines strongly recommend…
Abstract Number: 1682 • 2015 ACR/ARHP Annual Meeting
Suppression of Chronic Arthritis By a Novel Nuclear Factor of Activated T-Cell 5 (NFAT5) Inhibitor
Wan-Uk Kim¹, Eun-Jin Han², Chong-Hyeon Yoon³, Ki-Jo Kim⁴, Seung-Ah Yoo⁵, Bong Ki Hong⁵ and Saseong Lee⁵, ¹Internal Medicine, Seoul St. Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea, ²Institute of Bone & Joint Disease, The Catholic University of Korea, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, South Korea, ⁴St. Mary's Hospital, Seoul, South Korea, ⁵Institute of Bone and Joint Diseases, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: We reported that nuclear factor of activated T-cells 5 (NFAT5), originally identified as an osmo-protective transcription factor, has a critical role in the pathogenesis…
Abstract Number: 2761 • 2015 ACR/ARHP Annual Meeting
IL-6R Blockade with Sarilumab Plus Methotrexate Results in Changes in Clinical and Laboratory Parameters Associated with Chronic Inflammation in Patients with Moderate-to-Severe RA in a Phase 3 Study
Maxime Dougados¹, Ernest H. Choy², Hideto Kameda³, Janet van Adelsberg⁴, Jonathan Fay⁵, Stefano Fiore⁶, Chunpeng Fan⁷ and Georg Schett⁸, ¹Paris-Descartes University, Paris, France, ²Cardiff University, Institute of Infection and Immunity, Tenovus Building, University Hospital of Wales, Cardiff, United Kingdom, ³Dep of Rheumatol/Clin Immun, Saitama Medical Ctr, Kawagoe, Japan, ⁴Clinical Science, Regeneron Pharmaceutials, Inc., Tarrytown, NY, ⁵Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Sanofi, Bridgewater, NJ, ⁷Biostatistics, Sanofi, Bridgewater, NJ, ⁸Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Chronic inflammation in RA is characterized by biochemical changes, including decreased hemoglobin, elevated CRP, changes in lipid metabolism, and hypoalbuminemia.1 Some parameters, including CRP,…
Abstract Number: 168 • 2015 ACR/ARHP Annual Meeting
Ultrasound Evaluation of the Efficacy of Biologic and Targeted Synthetic Dmards Toward Rheumatoid Arthritis Patients: Kyushu Multicenter Rheumatoid Arthritis Ultrasound Prospective Observational Cohort in Japan
Ayako Nishino^1,2, Shin-ya Kawashiri^1,2, Atsushi Kawakami^1,2, Tamami Yoshitama², Nobutaka Eiraku², Noki Matsuoka², Yukitaka Ueki², Akitomo Okada², Hiroaki Hamada², Toshihiko Hidaka², Shuji Nagano², Tomomi Tsuru², Keita Fujikawa² and Yojiro Arinobu², ¹Department of Immunology and Rheumatology, Nagasaki University, Nagasaki, Japan, ²Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan
Background/Purpose: Few prospective ultrasound (US) cohort studies of rheumatoid arthritis (RA) patients treated by biologic or targeted synthetic DMARDs (b/tsDMARDs) are reported. We have been…
Abstract Number: 1288 • 2015 ACR/ARHP Annual Meeting
Dual Care Utilization in Patients Enrolled in the Veterans Affairs Rheumatoid Arthritis Registry
Pascale Schwab¹, Harlan Sayles², Debra Bergman³, Grant W. Cannon⁴, Kaleb Michaud⁵, Ted R. Mikuls² and Jennifer Barton¹, ¹VA Portland Health Care System, Portland, OR, ²University of Nebraska Medical Center, Omaha, NE, ³Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴Division of Rheumatology, Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Rheumatology & Immunology, University of Nebraska Medical Center and National Data Base for Rheumatic Diseases, Omaha, NE
Background/Purpose: While use of multiple health care systems may allow rapid access to medical care, the practice results in fragmented and redundant treatments at…
Abstract Number: 2050 • 2015 ACR/ARHP Annual Meeting
Herpes Zoster during the Tofacitinib Clinical Development Program for RA: Characterization of Herpes Zoster Incidence and Evaluation of Whether Herpes Zoster Predicts Subsequent Serious Infections or Malignancy
Kevin L. Winthrop¹, Yoshiya Tanaka², Kunihiro Yamaoka³, Jeffrey R. Curtis⁴, Chudy Nduaka⁵, Haiyun Fan⁵, Pinaki Biswas⁶, Tomohiro Hirose⁷, Sriram Krishnaswami⁸, Hernan Valdez⁶, Shigeyuki Toyoizumi⁷, Koshika Soma⁸ and Connie Chen⁶, ¹Oregon Health & Science University, Portland, OR, ²The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ³Keio University, Tokyo, Japan, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Japan Inc, Tokyo, Japan, ⁸Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The risk of herpes zoster (HZ) was elevated within the tofacitinib clinical…
Abstract Number: 2762 • 2015 ACR/ARHP Annual Meeting
Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients
Gerd Burmester¹, Anju Garg², Hubert van Hoogstraten², Neil Graham³, Alex Boddy², Janie Parrino⁴ and Mark C. Genovese⁵, ¹Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany, ²Sanofi, Bridgewater, NJ, ³Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴Merck & Co., Inc., Whitehouse Station, NJ, ⁵Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA
Background/Purpose: The investigational agent sarilumab is a human mAb directed against the IL-6 receptor. In the phase 3 MOBILITY study (NCT01061736), sarilumab (150 or 200…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].